Source REUTERS Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world’s priciest medicines. The full scope of Novartis’ $500 million plan, revealed to Reuters in an interview
Study in Nature Sheds New Light on Heart Attack Treatment Controversy Stem cell therapy helps hearts recover from a heart attack, although not for the biological reasons originally proposed two decades ago that today are the basis of ongoing clinical trials. This is the conclusion of a Nov. 27 study in Nature that shows an entirely different
Source Trends in Molecular Medicine Mitochondria and lysosomes are pivotal organelles for cellular metabolism and also have important roles as signaling platforms. Many diseases are characterized by impaired mitochondrial or lysosomal function. These are often referred to as ‘mitochondrial diseases’, which have a primary cause in mitochondria, or as lysosomal storage diseases. Although each specific
High-throughput synthetic biology approach reveals hidden AAV features and could help fast-track future gene therapies Adeno-associated viruses (AAVs) have become the go-to vehicle for delivering therapeutic gene cargo to target tissues for the wave of gene therapies that are in development in academic and biotechnology laboratories. However, natural AAVs do not specifically target diseased cells
For the first time, The Arthroscopy Association of North America (AANA), the American Orthopaedic Society for Sports Medicine (AOSSM), the International Cartilage Repair Society (ICRS) and the ON Foundation have collaborated to form The Biologics Alliance (BA)™, an orthopaedic organization dedicated to providing one voice for all matters on musculoskeletal biologics and regenerative medicine. Recently, randomized clinical trials and clinical practice guidelines
Funds paved the way for rigorous tests of therapies, but unintentionally boosted a market for potentially dangerous fakes, says Jeanne F. Loring. Source Nature For the past dozen or so years, stem-cell researchers in California have been the envy of the world. In 2004, as a rebuke to the restrictions put in place in the
New data released shows cell and gene therapy manufacturing facilities are rapidly becoming operational reflecting job expansion in the sector. Additional 6,000m2 of cell and gene therapy manufacturing space expected to become available within the next 12 months. The Cell and Gene Therapy Catapult (CGT Catapult) published the sixth annual UK cell and gene therapy
Using organoid technology, adult epithelial stem cells can be expanded in vitro to generate self organizing 3D epithelial structures that closely recapitulate the architecture and cellular composition of the tissue of origin. Because of their strict dependence on Wnt ligands for survival and growth, intestinal organoids have become the tool of choice for in vitro
European regulations might be responsible for lower numbers of advanced therapy clinical trials running in the region when compared to the US and Asia. Europe has historically been a pioneer in advanced therapies, such as cell and gene therapy. Europe was the first region to approve a gene therapy, and it boasts the highest number
Neuromuscular experts with the University of Miami Health System and the Miller School of Medicine will launch a Phase 1/2 clinical trial (NCT04146051) using the CAR-T drug, Descartes-08, to treat patients with generalized myasthenia gravis. Generalized myasthenia gravis (GMG) is a rare disease and a chronic autoimmune condition in which auto-antibodies attack specific proteins at the
